July 17, 2016: Thank you kindly for everyone's support. If you're interested in donating further, please visit https://riderinstitute.org/pages/donate. Thank you!
_________________________________________
We Hope DRACO Will Be A Cure For ALL Viruses! #EndTheVirus | RIDERinstitute.org
![]()
![]()
![]()
![]()
![]()
![]()
Dr. Rider’s DRACO approach and results have been called “visionary” by the White House (White House National Bioeconomy Blueprint, April 2012, p. 9), named one of the best inventions of the year by Time Magazine (November 18, 2011, pp. 58, 78), and featured on the BBC Horizons TV program (2013).
View our previous IndieGoGo campaign that raised $60,823.
DRACO has been effective against ALL viruses tested against! See the Journal of PLOS ONE results
Read 'Meet Todd Rider, the Man Who Maybe, Probably Cured Most of the Viruses on Earth' by Inverse.com![]()
Read 'This man's potentially huge medical breakthrough can't get funding, so he's trying something desperate' on Tech Insider.![]()
![]()
![]()
DRACOs (Double-stranded RNA Activated Caspase Oligomerizers) are broad-spectrum antiviral candidates developed by Dr. Todd Rider. They have proved safe and effective in treating ALL 18 viruses against which Dr. Rider has tested them in proof-of-concept work. Two different types of H1N1 influenza (flu), four types of rhinovirus (the common cold), two adenoviruses, dengue hemorrhagic fever, and others were among the 18 viruses that DRACOs have successfully treated in human and animal cells and in mice.
Check out the published results in the peer-reviewed journal PLOS ONE.
We are now raising funds to test and optimize DRACOs against the herpesvirus family, which contains many major clinical viruses such as Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2), Cytomegalovirus (CMV), Varicella Zoster Virus (VZV, chickenpox and shingles virus), Epstein-Barr Virus (EBV), and Kaposi's Sarcoma Herpesvirus (KSHV).
If we can raise enough funding, we also hope to test and optimize DRACOs against the family of retroviruses, which includes Human Immunodeficiency Virus (HIV) and Human T-Lymphotropic Virus (HTLV).
In principle, the DRACO approach should be effective against virtually all known viruses, or potentially even against new viruses that may appear. Join the movement to #EndTheVirus!
Donate and spread the word!
![Image and video hosting by TinyPic]()
Previously published on:
![]()
![]()
![]()
DRACOs could potentially...
![]()
A DRACO has already proved effective against four different rhinoviruses (common cold) strains in human cells and against H1N1 influenza (Swine Flu) in cells and in live mice!
![]()
(i.e; Ebola, swine & bird flu, SARS, MERS, Zika, Chikungunya etc.)
![]()
End the suffering and save the lives of those with incurable viruses (i.e; HIV/ AIDS, HSV (cold sores and genital herpes), herpes zoster virus (chickenpox/shingles), HTLV, HPV, etc...
![]()
However, research on DRACOs has entered the well-known “Valley of Death" (Source: NY Times), in which a lack of funding prevents DRACOs, and many other promising new drugs, from advancing toward human clinical trials.
DRACOs could potentially revolutionize the treatment and prevention of viral infections, just as the development of antibiotics revolutionized the treatment and prevention of bacterial infections in the mid-20th century.
With your help, we hope that DRACOs may ultimately end suffering and save lives of those struggling with any number of viruses.
![]()
![]()
![]()
![]()
By the process of efficiently eliminating only virus-infected cells, DRACOs may be able to permanently cure viral infections that can currently only be controlled but not cured by existing antiviral therapeutics.
![]()
When tested in human and animal cells, DRACOs have been nontoxic and effective against 18 different viruses, including rhinovirus (the common cold) and dengue hemorrhagic fever (see table below).
![]()
For more information on the results of previous DRACO experiments, see the article published in PLOS ONE.
Still looking for more explanation? Check out this great video!
![]()
The ultimate goal is to develop DRACOs as a therapeutic that might be able to treat or prevent virtually all viral infections. But in order for that to happen, we'll need the following:
Lab Space
![]()
UMass Lowell is an option that is available for us.
Equipment
![]()
![]()
![]()
Continued Research and Progression of Trials![]()
![]()
Timeline: When Might DRACOs Be Available?
The drug approval process is unfortunately long and complicated. What we know is that 4 years (or potentially less depending on funding and results) should be enough time for Dr.Rider to test and collect enough data on clinically relevant herpes viruses that should persuade partners to help advance DRACOs toward human clinical trials. We are committed to testing and optimizing DRACOs against clinically relevant viruses as rapidly and as thoroughly as funding will permit, and we hope to see DRACOs advance to human trials as soon as possible.
Risks & Challenges
The greatest challenge has been securing funding to help DRACO research progress. It is also important to note that while DRACO is based on sound scientific principles and has yielded promising experimental results thus far, biological systems are very complex and we can offer no guarantee that DRACO research will end with a pill in a bottle for everyone. Without your help, though, we may never find out.
![]()
Currently, DRACO development is in the Valley of Death (the financial and experimental gap between the previously funded National Institutes of Health proof-of-concept experiments and the threshold for convincing major pharmaceutical companies to advance DRACOs toward human trials). This campaign has been set up to raise the funding necessary to bridge that gap. With your assistance, we hope to obtain enough funding to test and optimize DRACOs against clinically relevant viruses in human cells.
Please visit our slideshow presentation for more details and examples by clicking HERE.
If successful, the results of those experiments should persuade pharmaceutical companies and other major sponsors to commit their own resources to advance DRACOs through large-scale animal trials and hopefully human trials. Without your assistance, DRACOs may never progress further, and their potential to revolutionize the treatment of viral infections may remain unfulfilled.
82% of your donation, less the $0.30 credit card fee on each transaction and overhead costs, will go directly to DRACOs research!
![]()
![]()
![]()
![]()
Dr.Todd H. Rider
![]()
Dr. Todd H. Rider studied both biomedicine and engineering at MIT, including coursework at Harvard Medical School, and has spent his career inventing novel biotechnology projects by combining molecular and cellular biology tools with a systems engineering approach. After receiving his Ph.D. from MIT, he worked at Aeiveos Corporation on in vitro experiments to test and potentially intervene in the molecular mechanisms of human aging. In 1997 he joined MIT Lincoln Laboratory and the MIT Center for Cancer Research and invented the CANARY biosensor, which uses genetically engineered lymphocytes to identify pathogens within seconds with very high accuracy and sensitivity. He engineered and demonstrated the first CANARY cell lines, as reported in his widely publicized 2003 Science paper. Dr. Rider invented the DRACO antiviral approach, designed the therapeutics and experiments, personally conducted many of the in vitro and in vivo experiments, and recruited and supervised a team in carrying out the rest. His DRACO research has been called “visionary” by the White House (National Bioeconomy Blueprint, April 2012, p. 9), named one of the best inventions of the year by Time magazine (November 28, 2011, pp. 58, 78), and featured on the BBC Horizons TV program (2013). He has also invented additional PANACEA anti-pathogen therapeutics, novel high-energy biofuel cells, and other projects. Along the way, Dr. Rider founded and runs the Science on Saturday program and other K-12 science outreach programs at MIT.
The Marketing Team
Behind the scenes we have been lucky to have the assistance of several marketing professionals and volunteers.
![]()
This is your chance, so please donate! You can help to advance the development of a therapeutic that may be effective against almost any viral infection. So please, choose to help push research forward by making a donation.
Other Ways You Can Help:
Not able to make a donation? That's okay. If you believe in our mission you can still help by spreading the word on your social media.
Share this link on facebook, twitter and via email: http://igg.me/at/EndTheVirus
![]()